The potential of multi-compound nanoparticles to bypass drug resistance in cancer C. G. Da SilvaGodefridus J. PetersLuis J. Cruz Review Article Open access 08 September 2017 Pages: 881 - 894
Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management Bryan OronskyScott CaroenCorey A. Carter Review Article Open access 20 July 2017 Pages: 895 - 907
Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy Xingjuan ShiXiaoou Sun Review Article 24 July 2017 Pages: 909 - 917
Animals living in polluted environments are a potential source of anti-tumor molecule(s) Shareni JeyamoganNaveed Ahmed KhanRuqaiyyah Siddiqui Review Article 09 August 2017 Pages: 919 - 924
Repositioning of proton pump inhibitors in cancer therapy Zhen-Ning LuBing TianXiu-Li Guo Review Article 31 August 2017 Pages: 925 - 937
Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107 Kei SatoChikara KunisakiItaru Endo Original Article 14 September 2017 Pages: 939 - 943
Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment Kyung KimReena JhaAiwu Ruth He Original Article 20 September 2017 Pages: 945 - 954
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002) Yasuyuki IkezawaHajime Asahinaon behalf of Hokkaido Lung Cancer Clinical Study Group Original Article 13 September 2017 Pages: 955 - 963
Innovative intraoral cooling device better tolerated and equally effective as ice cooling Java WalladbegiMartin GellerstedtMats Jontell Original Article Open access 03 October 2017 Pages: 965 - 972
miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1 Haifeng ZhangBaoli HuLi Li Original Article 27 September 2017 Pages: 973 - 984
Participation of MT3 melatonin receptors in the synergistic effect of melatonin on cytotoxic and apoptotic actions evoked by chemotherapeutics Roberto ParienteIgnacio BejaranoJosé A. Pariente Original Article 27 September 2017 Pages: 985 - 998
Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab Motoo NomuraAtsushi OtsukaManabu Muto Original Article 05 October 2017 Pages: 999 - 1004
Phase I study of a chloroquine–gemcitabine combination in patients with metastatic or unresectable pancreatic cancer Panagiotis SamarasMarina TusupSteve Pascolo Original Article 04 October 2017 Pages: 1005 - 1012
A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification Daniel MojHannah BritzThorsten Lehr Original Article 07 October 2017 Pages: 1013 - 1026
Inhibitory growth evaluation and apoptosis induction in MCF-7 cancer cells by new 5-aryl-2-butylthio-1,3,4-oxadiazole derivatives Rashmin KhanamKamal AhmadFareeda Athar Short Communication 16 August 2017 Pages: 1027 - 1042
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma Zhengqiu ZhouTracy A. HowardJohn L. Villano Short Communication 08 August 2017 Pages: 1043 - 1046